Optomed Oyj
OMXH:OPTOMED
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.945
7.27
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Optomed Oyj
Total Receivables
Optomed Oyj
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Total Receivables
€2.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Total Receivables
€14.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Total Receivables
€2.3m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Total Receivables
€1.5m
|
CAGR 3-Years
72%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Total Receivables
€2.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Total Receivables
€6.9m
|
CAGR 3-Years
70%
|
CAGR 5-Years
21%
|
CAGR 10-Years
24%
|
|
Optomed Oyj
Glance View
Optomed Oyj engages in the provision of handheld fundus cameras and eye-screening solutions. The company is headquartered in Oulu, Oulun and currently employs 115 full-time employees. The company went IPO on 2019-12-09. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.
See Also
What is Optomed Oyj's Total Receivables?
Total Receivables
2.7m
EUR
Based on the financial report for Dec 31, 2023, Optomed Oyj's Total Receivables amounts to 2.7m EUR.
What is Optomed Oyj's Total Receivables growth rate?
Total Receivables CAGR 5Y
-5%
Over the last year, the Total Receivables growth was -29%. The average annual Total Receivables growth rates for Optomed Oyj have been -10% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
